B. Riley Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its price objective trimmed by B. Riley from $9.00 to $7.00 in a report published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

PDSB has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Friday, November 15th. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. Finally, StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $2.15 on Monday. The firm has a market cap of $80.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.93. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The business has a 50-day simple moving average of $3.04 and a two-hundred day simple moving average of $3.16.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently made changes to their positions in PDSB. Vanguard Group Inc. lifted its holdings in PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after buying an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of PDS Biotechnology during the second quarter worth $146,000. XTX Topco Ltd grew its stake in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after acquiring an additional 47,528 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in PDS Biotechnology in the 2nd quarter valued at $120,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.